Skip to main content

Table 1 Baseline information of included studies for glioma diagnosis

From: Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis

Reference Year Country Design Specimens No. Patients No. Age, yr M/F Test Prior treatment Occurrence Gold Standard
Meana Median
Chen et al. [9] 2006 US Prospective 27 30 (27b) PET With or without 7 New+ 20 Recur Histo+Radio+follow-up
Tripathi et al. [10] 2009 India Prospective 15 15 28.4 ± 11.1 9/6 PET/CT With (Sx/CT/RT) or without 3 New+ 12 Recur Histo+Radio+follow-up
Sellam et al. [22] 2010 India Prospective 30 30 PET/CT Sx+/−RT Recur Histo+Radio+follow-up
Jora et al. [23] 2011 India Prospective 23 23 43.25 ± 14.9 PET/CT 15 with (Sx + RT) + 8 without 8 New+ 15 Recur Histo+Radio+follow-up
Karunanithi et al. [15] 2013 India Prospective 35 35 36.62 ± 0.86 28/7 PET/CT Sx + RT+/−CT Recur Histo+Radio+follow-up
Pafundi et al. [24] 2013 US Prospective 23 10 40.8 ± 18.9 9/1 PET/CT With or without 8 New+ 2 Recur Histo
Herrmann et al. [25] 2014 US Retrospective 110 110 51.7 ± 12.1 52.5 72/38 PET/CT Sx Recur Histo+Radio+follow-up
Moran et al. [26] 2015 Italy Retrospective 27 27 10 10 15/12 PET 1 with (Sx + CT + RT) + 20 without 20 New+ 1 Recur Histo+Radio+follow-up
Sharma et al. [27] 2016 India Prospective 12 11 34 6/5 PET/CT Sx Recur Histo+Radio+follow-up
Paquet et al. [28] 2017 France Prospective 60 35 60 PET Sx + CT + RT Recur Histo+Radio
Evangelista et al. [29] 2018 Italy Retrospective 13 13 60 PET/CT Unclear Recur Radio+follow-up
Youland et al. [30] 2018 US Prospective 37 13 40 9/4 PET Sx/CT/RT Recur Histo
Evangelista et al. [31] 2019 Italy Retrospective 21 21 58 ± 11 PET/CT Sx + CT/RT/immunotherapy Recur Radio+follow-up
  1. M male, F female, New newly-diagnosed, Recur recurrent, Histo histopathology, Radio radiology, Sx surgery, CT chemotherapy, RT radiation therapy
  2. aMean age is expressed as mean ± standard deviation
  3. bThree patients with brain metastases were excluded
\